Format

Send to

Choose Destination
Nat Rev Neurosci. 2013 Jun;14(6):401-16. doi: 10.1038/nrn3505. Epub 2013 May 15.

BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases.

Author information

1
GlaxoSmithKline, R&D China, Shanghai, 201203, China. bai.b.lu@gsk.com

Abstract

Increasing evidence suggests that synaptic dysfunction is a key pathophysiological hallmark in neurodegenerative disorders, including Alzheimer's disease. Understanding the role of brain-derived neurotrophic factor (BDNF) in synaptic plasticity and synaptogenesis, the impact of the BDNF Val66Met polymorphism in Alzheimer's disease-relevant endophenotypes - including episodic memory and hippocampal volume - and the technological progress in measuring synaptic changes in humans all pave the way for a 'synaptic repair' therapy for neurodegenerative diseases that targets pathophysiology rather than pathogenesis. This article reviews the key issues in translating BDNF biology into synaptic repair therapies.

PMID:
23674053
DOI:
10.1038/nrn3505
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center